PAPER Korologou-Linden R, Xu B, Coulthard E, Walton E, Wearn A, Hemani G, White T, Cecil C, Sharp T, Tiemeier H, Banaschewski T, Bokde A, Desrivières S, Flor H, Grigis A, Garavan H, Gowland P, Heinz A, Brühl R, Martinot JL, Paillère Martinot ML, Artiges E, Nees F, Orfanos DP, Paus T, Poustka L, Millenet S, Fröhner JH, Smolka M, Walter H, Winterer J, Whelan R, Schumann G, Howe LD, Ben-Shlomo Y, Davies NM, Anderson EL
SEARCH RESULTS
332771 RESULTS
PAPER Nozal V, Fernández-Gómez P, García-Rubia A, Martínez-González L, Cuevas EP, Carro E, Palomo V, Martínez A
Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation.
Biomed Pharmacother. 2024 Apr 24;175:116626. PubMed.PAPER Fu Y, Wang Y, Ren H, Guo X, Han L
Branched-chain amino acids and the risks of dementia, Alzheimer's disease, and Parkinson's disease.
Front Aging Neurosci. 2024;16:1369493. Epub 2024 Apr 10 PubMed.PAPER Wang S, Xie S, Zheng Q, Zhang Z, Wang T, Zhang G
Biofluid biomarkers for Alzheimer's disease.
Front Aging Neurosci. 2024;16:1380237. Epub 2024 Apr 10 PubMed.PAPER Mollah SA, Nayak A, Barhai S, Maity U
A comprehensive review on frontotemporal dementia: its impact on language, speech and behavior.
Dement Neuropsychol. 2024;18:e20230072. Epub 2024 Apr 22 PubMed.PAPER Yang LX, Luo M, Li SY
Tanshinone IIA improves Alzheimer's disease via RNA nuclear-enriched abundant transcript 1/microRNA-291a-3p/member RAS oncogene family Rab22a axis.
World J Psychiatry. 2024 Apr 19;14(4):563-581. PubMed.PAPER Ermini F, Low VF, Song JJ, Tan AY, Faull RL, Dragunow M, Curtis MA, Dominy SS
Ultrastructural localization of Porphyromonas gingivalis gingipains in the substantia nigra of Parkinson's disease brains.
NPJ Parkinsons Dis. 2024 Apr 25;10(1):90. PubMed.PAPER Carr LM, Mustafa S, Care A, Collins-Praino LE
More than a number: Incorporating the aged phenotype to improve in vitro and in vivo modeling of neurodegenerative disease.
Brain Behav Immun. 2024 Apr 23;119:554-571. PubMed.PAPER Patel Y, Woo A, Shi S, Ayoub R, Shin J, Botta A, Ketela T, Sung HK, Lerch J, Nieman B, Paus T, Pausova Z
Obesity and the cerebral cortex: Underlying neurobiology in mice and humans.
Brain Behav Immun. 2024 Apr 23;119:637-647. PubMed.PAPER Li WB, Xu LL, Wang SL, Wang YY, Pan YC, Shi LQ, Guo DS
Co-Assembled Nanoparticles toward Multi-Target Combinational Therapy of Alzheimer's Disease by Making Full Use of Molecular Recognition and Self-Assembly.
Adv Mater. 2024 Apr 25;:e2401918. PubMed.PAPER Orlandi F, Carlos AF, Ali F, Clark HM, Duffy JR, Utianski RL, Botha H, Machulda MM, Stephens YC, Schwarz CG, Senjem ML, Jack CR, Agosta F, Filippi M, Dickson DW, Josephs KA, Whitwell JL
Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.
Brain Commun. 2024;6(2):fcae113. Epub 2024 Apr 5 PubMed.PAPER Waiker DK, Verma A, Gajendra TA, Namrata, Roy A, Kumar P, Trigun SK, Srikrishna S, Krishnamurthy S, Davisson VJ, Shrivastava SK
Design, synthesis, and biological evaluation of some 2-(3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-yl)-N-phenylacetamide hybrids as MTDLs for Alzheimer's disease therapy.
Eur J Med Chem. 2024 May 5;271:116409. Epub 2024 Apr 16 PubMed.PAPER Abramov-Harpaz K, Lan-Mark S, Miller Y
Structural packing of the non-amyloid component core domain in α-synuclein plays a role in the stability of the fibrils.
Biophys Chem. 2024 Jul;310:107239. Epub 2024 Apr 16 PubMed.Thomas Foltynie on Diabetes Drug Shows Promise for Parkinson’s Disease
COMMENT This is an important publication, given it essentially replicates the findings of Athauda et al., who reported positive Phase 2 data of a very similar GLP-1 receptor agonist drug, exenatide, when given to patients with Parkinson’s disease (Athauda et al.,
Oscar Mailman
Pittsburgh, United States
Current Filters
No filters selected